Over the past few days HealthEquity (HQY -0.76%) shares have been rather sickly. The health savings account (HSA) specialist's stock was rocked by a disappointing earnings report, and as a result its price was down by nearly 15% week to date as of mid-afternoon Thursday, according to data compiled by S&P Global Market Intelligence.
HealthEquity divulged its fourth-quarter and full-year fiscal 2024 results just after market close on Tuesday. These showed that the company earned $311.8 million for the period ended Jan. 31, representing a year-over-year increase of 19%. Non-GAAP (adjusted) net income also saw a rise, improving by 11% to $61.3 million. On a per-share basis, that figure was $0.69.
This meant a mixed quarter for HealthEquity. While it beat the average analyst estimate of $305.8 million for revenue, it fell short of the consensus $0.72 projection for adjusted profitability.
In the earnings report, management attributed its improvements largely to volume. It said that it added a record 1 million new HSAs in fiscal 2024 to 9.9 million. Total HSA assets amounted to $32.1 billion at the end of that year, for an increase of 27% over fiscal 2023.
HealthEquity also proffered guidance for the entirety of fiscal 2025. The company is forecasting revenue of $1.28 billion to $1.305 billion; the high end of the range is 9% above the fiscal 2024 tally, which is somewhat disappointing given the past quarter's double-digit improvement. That $1.31 billion also sits below the consensus analyst expectation of $1.309 billion.
Adjusted net income, meanwhile, should come in at $318 million to $333 million, or $3.57 to $3.74 per share. Although the former projection is at least 15% higher than the actual fiscal 2024 result, on a per-share basis it doesn't quite reach the $3.76 collective projection from pundits.
While I think HealthEquity is in a good and potentially long-term lucrative business, that anticipated revenue growth slowdown is concerning. Hopefully management will be able to get the double-digit growth train running again.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.